MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
复制标题
DOI：
10.18632/oncotarget.4492
复制
发表时间：
2015-09-15
期刊：
影响因子：
--
通讯作者：
Silvestris N
中科院分区：
文献类型：
--
作者：
Brunetti O;Russo A;Scarpa A;Santini D;Reni M;Bittoni A;Azzariti A;Aprile G;Delcuratolo S;Signorile M;Gnoni A;Palermo L;Lorusso V;Cascinu S;Silvestris N
胰腺导管腺癌（PDAC）是一种预后不良、总生存期短且化疗选择很少的肿瘤。 MicroRNA (miRNA) 是大约 22 个核苷酸的非编码单链 RNA，参与癌发生和转移的致病机制。人们已经在许多肿瘤中对它们进行了研究，以确定潜在的诊断、预后或治疗靶点。在目前的文献中，许多研究分析了miRNA在PDAC中的作用。事实上，由于缺乏适当的生物标志物、这种肿瘤早期检测的困难以及无法切除的疾病患者缺乏有效的化疗，这些因素已经将 miRNA 的注意力集中到了这种恶性肿瘤的新的、有趣的进展上。在这篇综述中，我们分析了 miRNA 在 PDAC 中的作用，以了解作用机制以及癌 miRNA 和抑癌 miRNA 之间的差异。我们还回顾了与使用这些分子作为疾病过程中的预测和预后生物标志物相关的所有数据。最后，还讨论了 miRNA 或抗 miRNA 在 PDAC 中可能的治疗用途。总之，虽然这些分子在 PDAC 中仍然没有临床应用，但我们认为，特定 miRNA 在致癌作用中的作用的临床前证据、使用 miRNA 作为诊断或预后生物标志物的可能性及其潜在的治疗作用，保证了 PDAC 的未来研究。
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, interesting advance in this malignancy. In this review we analyzed the role of miRNAs in PDAC in order to understand the mechanisms of action and the difference between the onco-miRNA and the tumor suppressor miRNA. We also reviewed all the data related to the use of these molecules as predictive as well as prognostic biomarkers in the course of the disease. Finally, the possible therapeutic use of miRNAs or anti-miRNAs in PDAC is also discussed. In conclusion, although there is still no clinical application for these molecules in PDAC, it is our opinion that the preclinical evidence of the role of specific miRNAs in carcinogenesis, the possibility of using miRNAs as diagnostic or prognostic biomarkers, and their potential therapeutic role, warrant future studies in PDAC.